X

Gennex Laboratories Ltd. Stock Analysis

Small Cap
Evaluated by 324 users | BSE: 531739 | NSE: |
Pharmaceuticals & Drugs
Gennex Laboratories (formerly Prudential Pharmaceuticals) is a public limited company established in the year 1995 and has been engaged in the manufacturing of bulk drugs and intermediates. The company started as one of the leading manufacturer and exporter of bulk drugs and...

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Mar'10Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19
Return on Capital Employed -1.88%2.45%2.72%2.2%1.19%3.34%8.99%9.85%3.94%7.59%
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 15.119.324.629.93531.938.641.943.855.8
Y-o-Y Gr. Rt.-28%27.5%21.8%17%-8.8%20.9%8.7%4.5%27.5%
Adjusted EPS (Rs.) -0.050.040.040.030.010.050.190.220.070.17
Y-o-Y Gr. Rt.-NA0%-25%-66.7%400%280%15.8%-68.2%142.9%
Book Value per Share (Rs.) 1.91.931.961.992.012.022.232.452.512.69
Adjusted Net Profit -0.70.50.50.40.10.62.42.70.92.2
Net Op. Cash Flow (Rs. Cr.) 7.81.92.1-1.70.50.23.4-0.13.21.9
Debt to Cash Flow from Ops 0.240.830.9-1.396.5118.620.72-36.220.812.45
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Gennex Laboratories Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  9 yrs 5 yrs 3 yrs 1 yr
Net Sales 15.7%9.8%13.1%27.5%
Adjusted EPS NA76.2%-3.6%142.9%
Book Value per Share 3.966.57.2
Share Price 15.5% 5.5% 2.9% 20.1%
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'10Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19
Return on Equity (%) -2.681.892.061.60.442.498.739.242.726.72
Operating Profit Margin (%) 2.477.927.365.14.656.3410.8810.915.187.21
Net Profit Margin (%) -4.332.382.061.340.321.996.096.521.953.96
Debt to Equity 0.080.060.080.10.130.150.090.130.080.14
Working Capital Days 307112103129147181160185203161
Cash Conversion Cycle 654925-3-13-12610215
Entity Percentage Holding
Promoters 22.05%
Non-Institutions 77.95%
Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

The 5-year analysis of Gennex Lab's performance infers:

Gennex Lab earnings have grown by 76.2%, whereas share price has appreciated 5.5% CAGR over the past five years, indicating the company's share price is likely undervalued. However, for specific investment actions please connect with your investment advisor.

We analysed the performance of Gennex Lab share prices over the last 10 years. Here is what we found out:

Gennex Lab share price has appreciated 11.2% annually over the past ten years.

Gennex Laboratories (formerly Prudential Pharmaceuticals) is a public limited company established in the year 1995 and has been engaged in the manufacturing of bulk drugs and intermediates. The company started as one of the leading manufacturer and exporter of bulk drugs and intermediates. Quality is the strength of the company and major part of its finished products are exported to various countries viz. Germany, United Kingdom, Spain, Singapore, Canada, Switzerland, Iran, Bangladesh,

Gennex Laboratories (formerly Prudential Pharmaceuticals) is a public limited company established in the year 1995 and has been engaged in the manufacturing of bulk drugs and intermediates. The company started as one of the leading manufacturer and exporter of bulk drugs and intermediates. Quality is the strength of the company and major part of its finished products are exported to various countries viz. Germany, United Kingdom, Spain, Singapore, Canada, Switzerland, Iran, Bangladesh, Pakistan and other major countries. Gennex Laboratories has diversified its activities to biotech products in order to have better prospects and opportunities for the company for expanding its bussiness activities and to meet the marketing requirements.

The company had commenced its commercial operations of Guaifenesin in November, 1995 and in a span of about one and half years, it was able to capture about 70% of the domestic market mainly due to the impeccable quality, aggressive marketing strategies, cost effective manufacturing and efficient distribution cum market penetration. It has also established itself fairly well in the export market and recognized well by many end-users and trading giants of international market.

The company has catered to countries like USA, Mexico, Spain and Germany and the quality has been accepted and appreciated extremely well with all the customers. Several customers have evinced interest on long-term tie-ups. Slowly but surely, the company is constantly expanding its reach to USA and European markets and it has been receiving very encouraging enquiries from prospective customers based on quality recommendations by existing customers. The company’s headquarters is situated in the heart of the city and the factory is situated at Survey No 133, IDA Bollaram, Jinnaram Mandal, Medak District-502 325, Andhra Pradesh, India. The factory occupies a total land area of 8,000 square meters. The total building floor space is1,945 square meters. The storage space is 500 square meters. The central lab has a floor space of 225 square meters.

Products of the company:

  • Guaiphenesin
  • Methocarbamol
  • Fluconazole
  • Phenazopyridine

Certification:

  • Gennex Laboratories is an ISO 9001: 2008 approved company and obtained GMP Certification from the Central Drug Authority.
  • The company is also planning for ISO 14001: 2002 certification and OHSHAS 18000 to ensure its products are more widely accepted in the international market.
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323
Research Analyst - INH000000719

Callback